Abstract |
Pruritus is a significant problem for many patients undergoing long-term hemodialysis. Topical capsaicin depletes and prevents the reaccumulation of substance P in peripheral sensory neurons. Substance P functions in the transmission of pain and probably itch sensations. An open-label, uncontrolled trial and a double-blind, vehicle-controlled trial were conducted to evaluate the efficacy and safety of capsaicin 0.025% cream in the treatment of localized areas of pruritus in patients undergoing long-term hemodialysis. Eight of nine evaluable patients in the open-label trial reported marked relief or complete resolution of itching during the study period, and two of five evaluable patients in the double-blind trial reported complete resolution of itching in the capsaicin-treated arm with no or minimal improvement in the vehicle-treated arm. Twelve patients in the open-label trial and two in the double-blind trial were unevaluable. No serious treatment-related adverse reactions occurred.
|
Authors | D L Breneman, J S Cardone, R F Blumsack, R M Lather, E A Searle, V E Pollack |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 26
Issue 1
Pg. 91-4
(Jan 1992)
ISSN: 0190-9622 [Print] United States |
PMID | 1732343
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Administration, Topical
- Adult
- Aged
- Capsaicin
(administration & dosage, adverse effects)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Pruritus
(drug therapy, etiology)
- Renal Dialysis
(adverse effects)
|